Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with a basic header/footer and a Home link, indicating access to the study record is blocked. This places the page in an error state rather than loading its usual study details.
    Difference
    0.5%
    Check dated 2026-10-01T20:58:15.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    Deleted key study documents and metadata from the MARIPOSA-2 study page, including the Statistical Analysis Plan, Study Protocol, and IPD sharing information. Related terms and metadata were also removed to reduce access to protocol details and data-sharing resources on the page.
    Difference
    17%
    Check dated 2026-09-24T20:59:01.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The page revision was updated to v3.7.0, replacing the previous v3.6.6.
    Difference
    0.0%
    Check dated 2026-09-17T20:50:02.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6, indicating a newer version of the MARIPOSA-2 study page.
    Difference
    0.0%
    Check dated 2026-09-03T18:32:54.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    A new entry '2023 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, updating the record's funding metadata.
    Difference
    0.0%
    Check dated 2026-08-27T15:50:34.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The study timeline metadata was updated, with two date entries added and two removed, affecting milestone and update timestamps shown on the study record.
    Difference
    0.1%
    Check dated 2026-08-20T13:56:00.000Z thumbnail image

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.